Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AstraZeneca, Tufts Join For Neuroscience
by Michael McCoy
July 22, 2013
| A version of this story appeared in
Volume 91, Issue 29
AstraZeneca and Tufts University’s medical school will jointly establish a team of postdoctoral researchers at Tufts charged with advancing understanding of disorders of the brain. As part of a three-year agreement, the team will study biological targets of interest in the treatment of diseases including Alzheimer’s and Parkinson’s. AstraZeneca says the new team will complement its neuroscience innovative medicines unit, set up in 2012 to partner with external collaborators. The British firm ended in-house neuroscience research at the time.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter